Tesamorelin
Also known as: Egrifta
Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.
Pricing for Tesamorelin
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Tesamorelin
150 third-party tests across 28 vendors. Each card links to the full report.
For
Tesamorelin
by Verified Peptides· batch TM07261020J
For
Tesamorelin
by OROS Research· batch OR-LPTES5-526-B6
For
Tesamorelin
by Glacier Aminos· batch TES10GA-07
For
Tesamorelin
by Crush Research· batch CR-TSM20-0307-1
For
Tesamorelin
by Skye Peptides· batch TESA26-10-002
For
Tesamorelin
by Skye Peptides· batch TESA26-20-004
For
Tesamorelin
by NG Peptide· batch TSM20-3
For
Tesamorelin
by Ion Peptide· batch TSM10-05042026
For
Tesamorelin
by BioLongevity Labs· batch 28-3-46149
For
Tesamorelin
by BioLongevity Labs· batch 28-3-46136
For
Tesamorelin
by NG Peptide· batch TSM10-13
For
Tesamorelin
by Riptide Wellness· batch RWTES-10-1004
For
Tesamorelin
by Reta Peptide· batch 20260409
For
Tesamorelin
by NG Peptide· batch TSM11
For
Tesamorelin
by Peptidegurus· batch cmojgr3yn00259grxv12jfffy
For
Tesamorelin
by Peptide Tech· batch TSG-8475
For
Tesamorelin
by OROS Research· batch OR-LPTES5-326-B5
For
Tesamorelin
by Ion Peptide· batch TSM10-04042026
For
Tesamorelin
by Verified Peptides· batch cmojb57tr00tskirxbkigs5iy
For
Tesamorelin
by Blank Peptides· batch 665394
For
Tesamorelin
by Skye Peptides· batch TESA26-20-003
For
Tesamorelin
by Forge Performance Co.· batch Clear Red Cap
For
Tesamorelin
by Skye Peptides· batch TESA26-20-002
For
Tesamorelin
by Simple Peptide· batch TESM-032026-1
30 citations indexed for Tesamorelin
case-report · 2026
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).
review · 2026
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.
animal · 2026
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model
The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.
Study · 2026
P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants
Study · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
Study · 2026
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration.